MEREO BIOPHARMA GROUP PLC

09481161
Active London

Research and experimental development on biotechnology

0 employees website.com
Life sciences and medical technology Research and experimental development on biotechnology
M

MEREO BIOPHARMA GROUP PLC

09481161

Research and experimental development on biotechnology

Founded 10 Mar 2015 Active London, England 0 employees website.com
Life sciences and medical technology Research and experimental development on biotechnology

Previous Company Names

MEREO BIOPHARMA GROUP LIMITED 10 Mar 2015 — 3 Jun 2016
Accounts Submitted 20 May 2026 Next due 30 Jun 2026 9 days remaining
Confirmation Submitted 26 May 2026 Next due 9 Mar 2027 8 months remaining
Net assets £41M £20M 2025 year on year
Total assets £46M £30M 2025 year on year
Total Liabilities £5M £10M 2025 year on year
Charges 2
2 satisfied

Contact & Details

Contact

Registered Address

4th Floor, One Cavendish Place London W1G 0QF England

Telephone

0800 000 0000

Email

info@example.com

Website

www.example.com

Full company profile for MEREO BIOPHARMA GROUP PLC (09481161), an active life sciences and medical technology company based in London, England. Incorporated 10 Mar 2015. Research and experimental development on biotechnology. View financials, directors, shareholders, and filings.

Business Summary

This company specializes in providing innovative solutions and services across multiple sectors.

Products & Services

consulting software analytics integration

Reports

Credit Report

In-depth credit score, financial analysis, risk assessment and company intelligence.

Financials

Financials

Period 1 Jan → 31 Dec 2025
Type group
Next accounts 31 Dec 2025
Due by 30 Jun 2026 9 days remaining

Balance Sheet & P&L (2015–2025)

Cash in Bank

£40.99M

Decreased by £28.81M (-41%)

Net Assets

£40.92M

Decreased by £20.05M (-33%)

Total Liabilities

£5.00M

Decreased by £10.42M (-68%)

Turnover

£800.00k

Employees

N/A

Debt Ratio

11%

Decreased by 9 (-45%)

Financial History

Revenue, profit, EBITDA and key financial figures

2025
31 Dec Year End
2024
31 Dec Year End
P&L
Revenue
£142.3M
£128.7M
Gross Profit
£48.2M
£43.1M
Operating Profit
£22.4M
£19.8M
Net Profit
£18.1M
£15.9M
EBITDA
£31.5M
£28.2M
Assets
Cash
£24.7M
£21.3M
Total Assets
£89.4M
£82.1M
Liabilities
Total Liabilities
£45.2M
£41.8M
Key Metrics
Employees
1,247
1,156
Latest Revenue
£142.3M
Latest EBITDA
£31.5M
Cash Position
£24.7M

Funding

Fundraising & Grants

Funding Rounds 6
Grants 1

Investors (23)

Investor NameInvestor SinceParticipating Rounds
Investor 11Jul 2015Unknown/Other
Investor 12Jul 2015Unknown/Other
Investor 13Jul 2015Unknown/Other

Share Capital

Share Capital

Share allotments and capital structure

189 Allotments 739,644,390 Shares £321.54m Total
Date FromShare ClassShares AllottedAmount RaisedPrice/Share
27 Apr 202614,215£42.645£0.003
24 Feb 20261,551,695£5k£0.003
25 Jan 2026868,630£3k£0.003
10 Oct 202554,165£11k£0.21
10 Oct 2025119,935£91k£0.76

Officers

Officers

1 active 2 resigned
Status
Wyzga, MichaelDirectorAmericanUnited States7123 Apr 2019Active

Shareholders

Shareholders (12)

Justin Roberts
2.7%
Charles Sermon
0.6%

Persons with Significant Control

Persons with Significant Control (0)

0 Active 2 Ceased
Ceased
Ceased

Group Structure

Group Structure

MEREO BIOPHARMA GROUP PLC Current Company

Charges

Charges

2 satisfied

Properties

Properties

2 leasehold 2 total
AddressTenurePrice PaidDate Added
Fourth Floor, 1 Cavendish Place, London (W1G 0QF) CITY OF WESTMINSTER
Leasehold-3 Oct 2024
Fourth Floor, 1 Cavendish Place, London (W1G 0QF) CITY OF WESTMINSTER
Leasehold-16 Sept 2015
Fourth Floor, 1 Cavendish Place, London (W1G 0QF)
Leasehold
Added 3 Oct 2024
District CITY OF WESTMINSTER
Fourth Floor, 1 Cavendish Place, London (W1G 0QF)
Leasehold
Added 16 Sept 2015
District CITY OF WESTMINSTER

Documents

Company Filings

DateCategoryDescriptionDocument
1 Jun 2026ResolutionResolutions
27 May 2026OfficersTermination of Annalisa Jenkins as director on 14 May 2026
26 May 2026Confirmation StatementConfirmation statement made on 23 Feb 2026 with updates
20 May 2026AccountsAnnual accounts made up to 31 Dec 2025
14 May 2026CapitalAllotment of shares (GBP 2,394,279.132) on 27 Apr 2026
1 Jun 2026 Resolution

Resolutions

27 May 2026 Officers

Termination of Annalisa Jenkins as director on 14 May 2026

26 May 2026 Confirmation Statement

Confirmation statement made on 23 Feb 2026 with updates

20 May 2026 Accounts

Annual accounts made up to 31 Dec 2025

14 May 2026 Capital

Allotment of shares (GBP 2,394,279.132) on 27 Apr 2026

Recent Activity

Latest Activity

Resolutions

2 weeks ago on 1 Jun 2026

Termination of Annalisa Jenkins as director on 14 May 2026

3 weeks ago on 27 May 2026

Confirmation statement made on 23 Feb 2026 with updates

3 weeks ago on 26 May 2026

Annual accounts made up to 31 Dec 2025

1 months ago on 20 May 2026

Allotment of shares (GBP 2,394,279.132) on 27 Apr 2026

1 months ago on 14 May 2026